Cellectar Biosciences Inc (CLRB.OQ)
1.12USD
20 Apr 2018
$-0.02 (-1.75%)
$1.14
$1.14
$1.15
$1.09
56,754
37,052
$2.14
$1.05
About
Overall
| Beta: | 1.02 |
| Market Cap(Mil.): | $23.88 |
| Shares Outstanding(Mil.): | 13.92 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| CLRB.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 30.95 | 32.74 |
| EPS (TTM): | -1.24 | -- | -- |
| ROI: | -103.68 | 14.84 | 14.38 |
| ROE: | -105.20 | 16.34 | 16.07 |
BRIEF-Cellectar Biosciences Appoints Brian M. Posner As Chief Financial Officer
* CELLECTAR BIOSCIENCES APPOINTS BRIAN M. POSNER AS CHIEF FINANCIAL OFFICER
BRIEF-Cellectar Granted Seminal U.S. Patent For Phospholipid-Ether Analogs As Cancer-Targeting Drug Vehicles
* CELLECTAR GRANTED SEMINAL U.S. PATENT FOR PHOSPHOLIPID-ETHER ANALOGS AS CANCER-TARGETING DRUG VEHICLES Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)
BRIEF-Cellectar Reports 2017 Financial Results
* CELLECTAR REPORTS 2017 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE
BRIEF-Cellectar Biosciences Gets Granted Orphan Drug Designation For CLR 131 To Treat Neuroblastoma
* CELLECTAR BIOSCIENCES GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT NEUROBLASTOMA
BRIEF-Cellectar Receives USPTO Notice Of Allowance For Patent Covering Use Of CLR 131 In Multiple Myeloma
* CELLECTAR RECEIVES USPTO NOTICE OF ALLOWANCE FOR PATENT COVERING USE OF CLR 131 IN MULTIPLE MYELOMA Source text for Eikon: Further company coverage:
BRIEF-Cellectar Biosciences On Jan 3, Notified Affected Employees Of Its Plan To Reduce Its Workforce By 6 Positions
* CELLECTAR BIOSCIENCES - ON JAN 3, NOTIFIED AFFECTED EMPLOYEES OF ITS PLAN TO REDUCE ITS WORKFORCE BY 6 POSITIONS -SEC FILING
BRIEF-Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort In Phase 2 Trial of CLR 131
* CELLECTAR ANNOUNCES EXPANSION OF RELAPSED/REFRACTORY MULTIPLE MYELOMA COHORT IN PHASE 2 TRIAL OF CLR 131
BRIEF-Cellectar Biosciences posts Q3 loss of $0.26 per share
* Cellectar Biosciences reports third quarter 2017 financial and corporate performance
BRIEF-Cellectar updates median overall survival from phase 1 trial in advanced multiple myeloma
* Cellectar announces updated median overall survival of 26.2 months from cohort 1 of clr 131 phase 1 trial in advanced multiple myeloma Source text for Eikon: Further company coverage:
BRIEF-Cellectar Biosciences announces new preclinical data
* New preclinical data suggest that Cellectar Biosciences' PDC platform provides enhanced outcomes in combination with external radiation
Competitors
| Price | Chg | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $126.66 | -0.89 |
| Bayer AG (BAYGn.DE) | €99.00 | -0.60 |
| Bayer AG (BAYE.F) | -- | -- |
| Sanofi SA (SASY.PA) | €65.28 | -0.32 |
| Roche Holding Ltd. (ROG.S) | CHF215.65 | -0.85 |
| Roche Holding Ltd. (RO.S) | CHF220.00 | -0.20 |
| Bristol-Myers Squibb Co (BMY.N) | $51.17 | -0.44 |
| Bristol-Myers Squibb Co (BMYMP.PK) | $1,306.55 | -- |
| Pfizer Inc. (PFE.N) | $36.63 | +0.10 |
| Spectrum Pharmaceuticals, Inc. (SPPI.OQ) | $18.47 | -0.39 |
Estimates